Northwire Canada EditionMonday, July 20, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Production / Operations

Quantum Biopharma appoints Antel clinical adviser

By The Northwire Desk — AI Analysis Oct 01, 2025 · 17:59 QNTM · 23.45 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma announced the appointment of Dr. Jack Antel, a world‑renowned multiple sclerosis expert, as a clinical development advisor for its Lucid‑MS program.
  • Dr. Antel will assist in designing efficacy trials as the company prepares to advance Lucid‑MS into a Phase 2 study.
  • The addition complements existing adviser Dr. Peter Stys and underscores Quantum’s commitment to accelerating its MS pipeline.

Key Details

  • Appointee: Dr. Jack Antel, professor of neurology (McGill University), former chair of the Department of Neurology & Neurosurgery, and past national scientific director of the endMS Research and Training Network.
  • Role: Clinical development advisor for Lucid‑MS, focusing on trial design and efficacy assessment in multiple sclerosis patients.
  • Program Context: Lucid‑MS (Lucid‑21‑302) is a patented investigational NCE aimed at inhibiting demyelination; preclinical data show prevention and reversal of myelin degradation.
  • Current Development Stage: Preparing to enter Phase 2 clinical trials seeking an efficacy signal in people with MS.
  • Existing Advisory Team: Dr. Peter Stys (University of Calgary) continues as a clinical adviser, providing continuity and additional expertise.
  • Executive Comments:
  • Dr. Andrzej Chruscinski (VP, Scientific & Clinical Affairs) highlighted Dr. Antel’s knowledge will be “instrumental in advancing Lucid‑MS into a phase 2 clinical trial.”
  • Prof. Lakshmi P. Kotra (Director) expressed honor at Dr. Antel’s involvement and confidence in his contribution to the program.

Notable Quotes

  • “We are excited that Dr. Antel will be joining Quantum as a new clinical adviser. He brings a wealth of knowledge on MS that will be instrumental in advancing Lucid‑MS into a phase 2 clinical trial looking for an efficacy signal in people with MS.” – Dr. Andrzej Chruscinski
  • “Dr. Jack Antel is among the giants worldwide in the field of multiple sclerosis clinical and basic research… I am honoured that he joined our Quantum team to support the clinical development program in MS.” – Prof. Lakshmi P. Kotra
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other